Top-News

PTC Therapeutics Aktie News

Aktie
WKN:  A1W0MW ISIN:  US69366J2006 US-Symbol:  PTCT Branche:  Biotechnologie Land:  USA
67,00 €
-0,50 €
-0,74%
15:13:42 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-9,58
Index-Zuordnung
-

PTC Therapeutics News

07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
06.05.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results PR Newswire
05.05.25 - PR Newswire
PTC518 PIVOT-HD Study Achieves Primary Endpoint
PTC518 PIVOT-HD Study Achieves Primary Endpoint PR Newswire
01.05.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.04.25 - PR Newswire
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
24.04.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
17.04.25 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results PR Newswire
28.03.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
28.03.25 - PR Newswire
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe PR Newswire
20.03.25 - PR Newswire
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies PR Newswire
27.02.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
20.02.25 - PR Newswire
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
19.02.25 - PR Newswire
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia PR Newswire
13.01.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
13.01.25 - PR Newswire
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »